Targeting CDH17 in Cancer: When Blocking the Ligand Beats Blocking the Receptor?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29084915.
- Also identified by DOI 10.1158/1078-0432.CCR-17-2823.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cadherin-17 (CDH17) has been implicated as protumorigenic for many years, but mechanisms have been unclear. A Spanish team has generated antibodies to an RGD motif in CDH17 that inhibits integrin α2β1 binding to CDH17 and thereby inhibits integrin activation, tumorigenesis, and metastasis. These reagents may have therapeutic potential. <i>Clin Cancer Res; 24(2); 253-5. ©2017 AACR</i><i>See related article by Bartolomé et al., p. 433</i>.
Medical subject headings
- Colorectal Neoplasms
- Melanoma